A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer

Bolin Chen, Wenxiu Yao, Xingya Li, Gen Lin, Qian Chu, Hailong Liu, Yingying Du, Jie Lin, Huaxin Duan, Huijuan Wang, Zemin Xiao, Hong Sun, Liyu Liu, Li Xu, Yan Xu, Fang Xu, Yi Kong, Xingxiang Pu, Kang Li, Qianzhi Wang, Jia Li, Baiyong Li, Yu Xia, Lin Wu